07:40 AM EDT, 10/28/2025 (MT Newswires) -- LSL Pharma Group (LSL.V) said Tuesday that Health Canada has approved its first six sterile ophthalmic solutions for the treatment of glaucoma and allergies. The commercial launch of these products is expected to begin in the second quarter of next year.

This approval strengthens LSL Pharma's presence in the sterile ophthalmic pharmaceuticals sector. The products have an aggregate commercial markets of $66 million in Canada, the company said.

"Obtaining these approvals from Health Canada represents a significant step forward for our Steri-Med Pharma division and another important step in the implementation of LSL Pharma's growth plan," said Francois Roberge, chief executive officer. "These new sterile ophthalmic products are the starting point for a broader portfolio of eye-care products that we will continue to expand in the coming months."